Loading clinical trials...
Loading clinical trials...
Speech assessment is a substudy to the STIMPulseControl study (hereinafter referred to as the main study), where audio recordings of patients voices will be recorded as part of a speech analysis in the main study, for this optional ancillary study.
Speech of all study patients enrolled in the STIMPulseControl main study will be recorded at three points of time in a standardized way. Following this ancillary protocol, patients speech will be recorded at the baseline visit (preoperatively), at the 6-months visit and at the 12-months visit postoperatively. For the baseline speech assessment the same protocol will be performed in chronic medication conditions. At 12-month follow up, we will repeat the speech protocol in chronic medication and stimulation condition. The recordings will be done in each centre in a decentralized way and the audio files will be produced according to a standardized protocol, and assisted by a step-by-step guided speech recording software. Main aims and hypothesis for automated speech analysis study are safety measures for surgical interventions in PD assessment of parkinsonian (hypokinetic) motor speech features outcome after STN-DBS, assessment of dyskinetic (hyperkinetic) motor speech features outcome after STN-DBS, assessment of capsular speech features outcome after STN-DBS in PD emotional and cognitive speech outcomes to be used in surgical and pharmacological interventions in PD assessment of acoustic and linguistic speech features as proxy for behaviour and cognitive changes in PD, comparison of emotional and cognitive speech outcomes before and 1-year after STN-DBS + BMT vs BMT alone.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
University Hospital Cologne
Cologne, Germany
University Hospital Carl Gustav Carus
Dresden, Germany
University Hospital Duesseldorf
Düsseldorf, Germany
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
University Hospital Schleswig-Holstein (UKSH), Campus Kiel
Kiel, Germany
University Hospital of Giessen and Marburg (UKGM), Campus Marburg
Marburg, Germany
Charité Campus Mitte
Mitte, Germany
University Hospital Tuebingen
Tübingen, Germany
University Hospital Wuerzburg
Würzburg, Germany
Amsterdam University Medical Center
Amsterdam, Netherlands
Start Date
September 5, 2024
Primary Completion Date
July 15, 2027
Completion Date
July 15, 2028
Last Updated
December 2, 2025
60
ESTIMATED participants
bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper
PROCEDURE
best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
DRUG
Lead Sponsor
Steffen Paschen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640